Stockscreener 앱 받기
1.11
4.31%
-0.05
시간 외 거래:
1.11
전일 마감가:
$1.16
열려 있는:
$1.16
하루 거래량:
9,025
Relative Volume:
0.32
시가총액:
$48.73M
수익:
-
순이익/손실:
$-7.92M
주가수익비율:
-3.70
EPS:
-0.3
순현금흐름:
$-7.05M
1주 성능:
-11.20%
1개월 성능:
-30.62%
6개월 성능:
-38.67%
1년 성능:
-59.64%
1일 변동 폭
$1.0783
$1.20
1주일 범위
$1.0783
$1.25
52주 변동 폭
$0.8001
$3.30
아네불로 파마슈티컬 Stock (ANEB) Company Profile
명칭
Anebulo Pharmaceuticals Inc
전화
737 203 5270
주소
JFL CAPITAL MANAGEMENT, LAKEWAY
ANEB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANEB
Anebulo Pharmaceuticals Inc
|
1.11 | 48.73M | 0 | -7.92M | -7.05M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
아네불로 파마슈티컬 주식(ANEB)의 최신 뉴스
Benchmark maintains Speculative Buy on Anebulo stock, target at $8 By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue - Investing.com
Anebulo Pharmaceuticals files to sell 15.15M shares of common stock for holders - MSN
Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results - TipRanks
Anebulo Pharmaceuticals Inc Files Prospectus Related To Resale Of 15.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing - Marketscreener.com
Anebulo Pharmaceuticals Inc. (ANEB) reports earnings - Quartz
Anebulo Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Anebulo Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Anebulo's Cannabis Overdose Treatment Gets FDA Priority Signal as Company Raises $15M - StockTitan
Head to Head Contrast: ProQR Therapeutics (NASDAQ:PRQR) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 By Investing.com - Investing.com Nigeria
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 - MSN
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks - Yahoo Finance
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Increases By 2,174.1% - Defense World
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Expands By 2,174.1% - Defense World
3 US Penny Stocks With Market Caps Under $800M - Yahoo Finance
Anebulo Pharmaceuticals sees $9.99m stock acquisition by 22NW fund - Investing.com Australia
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant - Yahoo Finance
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise - BioSpace
Anebulo Pharmaceuticals secures $15 million capital raise - Investing.com
Anebulo Reports Breakthrough Clinical Data for Cannabis Toxicity Treatment, Secures $15M Funding - StockTitan
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 9.8% – Should You Sell? - Defense World
Anebulo Pharmaceuticals stock hits 52-week low at $1.23 - Investing.com India
Anebulo Pharmaceuticals stock hits 52-week low at $1.23 By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 By Investing.com - Investing.com Australia
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 - Investing.com India
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions - MSN
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates - Defense World
Anebulo Pharma Secures $1.9M NIDA Grant for Cannabis Toxicity Treatment Development | ANEB Stock News - StockTitan
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com UK
Exxaro Resources (OTCMKTS:EXXAY) Share Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
Short Interest in Janone Inc. (NASDAQ:ALTS) Expands By 10.2% - Defense World
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Anebulo Pharmaceuticals Updates Corporate Presentation - TipRanks
Anebulo To Report Acute Cannabinoid Intoxication Trial Data In June - RTTNews
Benchmark maintains Speculative Buy on Anebulo stock By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals (NASDAQ:ANEB) Earns "Speculative Buy" Rating from Benchmark - MarketBeat
아네불로 파마슈티컬 (ANEB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):